ASPIRA PATHLAB & DIAGNOSTICS LIMITED Aspira Pathlab & Diagnostics Limited Stock
Equities
ASPIRA
INE500C01017
Healthcare Facilities & Services
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 32.5 INR | +1.56% |
|
+8.05% | -17.05% |
| Apr. 03 | Aspira Pathlab Forms New Limited Liability Partnership | MT |
| Apr. 01 | Aspira Pathlab Opens Two Diagnostic Centers in India | MT |
| Sales 2022 | 195M 2.34M | Sales 2023 | 145M 1.73M | Capitalization | 287M 3.44M |
|---|---|---|---|---|---|
| Net income 2022 | 44M 527K | Net income 2023 | - 0 | EV / Sales 2022 | 3.53 x |
| Net Debt 2022 | 22.78M 273K | Net Debt 2023 | 9.64M 116K | EV / Sales 2023 | 2.05 x |
| P/E ratio 2022 |
15
x | P/E ratio 2023 |
-309
x | Employees | 105 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 11.57% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.56% | ||
| 1 week | +8.05% | ||
| Current month | +4.84% | ||
| 1 month | +4.84% | ||
| 3 months | -1.84% | ||
| 6 months | -10.12% | ||
| Current year | -17.05% |
1 week
29.60
32.79
1 month
27.5036.50
Current year
27.5039.74
1 year
22.7649.50
3 years
22.76124.15
5 years
20.00124.15
10 years
14.15124.15
| Managers | Title | Age | Since |
|---|---|---|---|
Pankaj J. Shah
CEO | Chief Executive Officer | - | - |
| Director of Finance/CFO | - | - | |
Krupali Shah
CMP | Compliance Officer | - | 23-08-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 63 | 18-10-26 | |
| Chairman | 73 | 17-01-31 | |
| Director/Board Member | 69 | 15-09-27 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-30 | 32.5 | +1.56% | 447 |
| 24-04-29 | 32 | +1.27% | 189 |
| 24-04-26 | 31.6 | -2.14% | 280 |
| 24-04-25 | 32.29 | +4.84% | 1,136 |
| 24-04-24 | 30.8 | +0.52% | 380 |
Delayed Quote Bombay S.E., April 30, 2024 at 06:00 am EDT
More quotes
Aspira Pathlab & Diagnostics Limited is an India-based company, which is engaged in the business of running, owning, managing, and administering Diagnostics Centers. The principal activities of the Company consist of pathology investigation services, radiology investigation services and other related healthcare services at diagnostic centers in Mumbai. The Company carries out pathological investigations in various branches, including biochemistry, hematology, histopathology, microbiology, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. The Company's tests include COVID-19 tests, health packages and pathology tests. Its COVID-19 tests include Shanti Screening Test, COVID-19 Antibody Test, COVID-19 Surveillance Profile, COVID-19 RT-PCR Test, COVID-19 Detection Profile 1, and COVID-19 Detection Profile 2.
Calendar
2024-05-29
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -17.05% | 3.95M | |
| -16.55% | 8.43B | |
| +39.49% | 3.62B | |
| -38.71% | 2.61B | |
| -8.06% | 2.48B | |
| -7.96% | 2.34B | |
| -13.97% | 1.94B | |
| -19.73% | 1.56B | |
| -40.78% | 1.26B | |
| +8.32% | 1.1B |
- Stock Market
- Equities
- ASPIRA Stock
